News Releases
by Year
2012
Dec. 27, 2012 (PDF/123KB) Licensing
Signing a license agreement and a joint research agreement for new anti-cancer drug candidate compounds targeting the Ras signaling pathway
Nov. 22, 2012 (PDF/64KB) Products
Dainippon Sumitomo Pharma and Shionogi Announce the NHI Drug Price Standard Listing and Launch of anti-hypertension drug "AIMIX Combination Tablets LD/HD"
Oct. 31, 2012 (PDF/512KB) Finances
Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2013
Oct. 31, 2012 (PDF/238KB) Finances
Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2013 (Unaudited)
Oct. 31, 2012 (PDF/108KB) R&D
Sunovion Pharmaceuticals Inc. Announces FDA Acceptance of Two Supplemental New Drug Applications for the Use of Latuda (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Depressive Episodes Associated with Bipolar I Disorder
Oct. 25, 2012 (PDF/124KB) R&D
DSP and Takeda Announce the Acceptance of the European Medicines Agency Submission of an Atypical Antipsychotic Agent Lurasidone
Sep. 28, 2012 (PDF/72KB) Products
Dainippon Sumitomo Pharma obtains manufacturing and marketing approval for "AIMIX Combination Tablets LD/HD"
Sep. 18, 2012 (PDF/164KB) Products
Sunovion Pharmaceuticals Canada Inc. Announces the Launch of Once-Daily Latuda (lurasidone HCl) for the Treatment of Patients with Schizophrenia
Sep. 07, 2012 (PDF/187KB) R&D
Sunovion Pharmaceuticals Files Two Supplemental New Drug Applications Seeking Approval for the use of Latuda (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Depressive Episodes Associated with Bipolar I Disorder
Sep. 06, 2012 (PDF/33KB) Corporate
Sunovion Pharmaceuticals Inc. Completes Acquisition of Elevation Pharmaceuticals, Inc.
Sep. 05, 2012 (PDF/98KB) R&D
Dainippon Sumitomo Pharma submits an application for anticancer antibiotic amrubicin HCI (Brand name in Japan: CALSED) in China
Aug. 31, 2012 (PDF/59KB) Corporate
Dainippon Sumitomo Pharma Co., Ltd.'s U.S. Subsidiary Sunovion Pharmaceuticals Inc. to Acquire Elevation Pharmaceuticals, Inc. (US Biopharmaceutical Company)
Aug. 20, 2012 (PDF/103KB) Corporate
Dainippon Sumitomo Pharma announces organizational changes:Establishment of the "DSP Cancer Institute"
Jul. 31, 2012 (PDF/102KB) Products
Sunovion Pharmaceuticals Inc. Announces Nationwide Availability of ZETONNA (ciclesonide) Nasal Aerosol for Allergic Rhinitis
Jul. 27, 2012 (PDF/500KB) Finances
Supplementary Financial Data for the First Quarter of the Year Ending March 31, 2013
Jul. 27, 2012 (PDF/153KB) Finances
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2013 (Unaudited)
Jul. 27, 2012 (PDF/47KB) Finances
Revision of Financial Forecasts
Jul. 27, 2012 (PDF/84KB) R&D
Dainippon Sumitomo Pharma and Nitto Denko Joint Development Phase 2 studies start on the world's first transdermal patch formulation for schizophrenia treatment
Jul. 27, 2012 (PDF/51KB) Products
SUNOVION PHARMACEUTICALS RECEIVES SIX MONTH U.S. PEDIATRIC EXCLUSIVITY FOR LUNESTA (eszopiclone)
Jun. 26, 2012 (PDF/105KB) Products
Dainippon Sumitomo Pharma announces the launch of Sleep Inducing Treatment "Zolpidem tartrate tablets 5mg/10mg [DSP]"
Jun. 22, 2012 (PDF/88KB) Products
Dainippon Sumitomo Pharma obtains manufacturing and marketing approval for long-acting calcium antagonist AMLODIN tablets/OD tablets for the Additional Indication of "Hypertension in pediatric patients"
Jun. 22, 2012 (PDF/114KB) Products
Anti-depressant Paxil CR Tablets newly launched
Jun. 16, 2012 (PDF/25KB) Products
Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of Once-Daily LATUDA (lurasidone HCl) for the Treatment of Patients with Schizophrenia
Jun. 05, 2012 (PDF/40KB) Licensing
Dainippon Sumitomo Pharma and Shionogi to Sign a License Agreement for the Co-marketing of “DSP-8153”, Combination Product of Anti-hypertension Drugs irbesartan and amlodipine besilate
May 25, 2012 (PDF/22KB) Corporate
Sunovion Pharmaceuticals settles dispute on BROVANA patent litigation
May 10, 2012 (PDF/383KB) Finances
Supplementary Financial Data for the Year Ended March 31, 2012
May 10, 2012 (PDF/349KB) Finances
Summary of Consolidated Financial Results for the Year Ended March 31, 2012 (Unaudited)
May 10, 2012 (PDF/46KB) Corporate
Change of Members of Board of Directors and Executive Officer
May 10, 2012 (PDF/113KB) Products
New Study Shows Patients Can Effectively be Switched to Latuda (lurasidone HCl) from Other Antipsychotic Agents
May 08, 2012 (PDF/93KB) Products
SUNOVION ANNOUNCES UPCOMING AVAILABILITY OF ZETONNA (ciclesonide) NASAL AEROSOL, A NON-AQUEOUS, DRY NASAL AEROSOL SPRAY FOR ALLERGIC RHINITIS
May 07, 2012 (PDF/118KB) R&D
Dainippon Sumitomo Pharma Co. Reports that Latuda (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase III Trials in Bipolar I Depression (Updated version)
May 07, 2012 (PDF/94KB) Products
Latuda (lurasidone HCl) Label Updated With Expanded Dosing Range Providing Added Flexibility for the Treatment of Patients with Schizophrenia
Apr. 25, 2012 (PDF/31KB) Corporate
Dainippon Sumitomo Pharma Co., Ltd. Completes Acquisition of Boston Biomedical, Inc. (US Biotechnology Company)
Apr. 25, 2012 (PDF/62KB) Corporate
Change of Executive Officer
Apr. 24, 2012 (PDF/118KB) R&D
Dainippon Sumitomo Pharma Co. Reports that Latuda (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase III Trials in Bipolar I Depression
Apr. 17, 2012 (PDF/44KB) R&D
Dainippon Sumitomo Pharma submits an application for SUREPOST, a rapid-acting insulin secretagogue, for the additional indication of combination therapy with thiazolidinediones and with biguanides
Apr. 12, 2012 (PDF/63KB) Corporate
Change of Executive Officer
Mar. 30, 2012 (PDF/90KB) Products
GlaxoSmithKline and Dainippon Sumitomo Pharma commence the co-promotion of anti-depressant Paxil CR Tablets
Feb. 29, 2012 (PDF/58KB) Corporate
Dainippon Sumitomo Pharma Co., Ltd. to Acquire Boston Biomedical Inc. (US Biotechnology Company)
Feb. 23, 2012 (PDF/55KB) Corporate
Change of Representative Directors and Executive Officers
Feb. 20, 2012 (PDF/85KB) R&D
Dainippon Sumitomo Pharma Submits Application Based on Public Knowledge for long-acting calcium antagonist AMLODIN tablets/OD tablets for the Additional Indication of "Hypertension in pediatric patients"
Feb. 20, 2012 (PDF/105KB) Products
Dainippon Sumitomo Pharma obtains manufacturing and marketing approval for Sleep Inducing Treatment "Zolpidem tartrate tablets 5mg/10mg [DSP]"
Feb. 03, 2012 (PDF/469KB) Finances
Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2012
Feb. 03, 2012 (PDF/284KB) Finances
Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2012 (Unaudited)
Feb. 03, 2012 (PDF/44KB) Finances
Revision of Financial Forecasts for the Year Ending March 31, 2012
Jan. 30, 2012 (PDF/142KB) Corporate
Dainippon Sumitomo Pharma Begins Construction on New Chemistry Research Building
Jan. 19, 2012 (PDF/98KB) Products
Announcement of basic agreement concerning co-promotion of anti-depressant Paxil® CR Tablets